Quick Answer
Indivior Pharmaceuticals, Inc. reported Operating Income of $262.00 million for fiscal year 2025.
Indivior Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $262.00M | +589.5% |
| 2024 | $38.00M | +125.0% |
| 2023 | -$152.00M | -87.7% |
| 2022 | -$81.00M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $43.00M | +22.9% | -40.3% |
| June 30, 2025 | $72.00M | +161.0% | +9.1% |
| March 31, 2025 | $66.00M | -12.0% | +43.5% |
| December 31, 2024 | $46.00M | — | +31.4% |
| September 30, 2024 | $35.00M | — | +129.7% |
| June 30, 2024 | -$118.00M | — | -257.3% |
| March 31, 2024 | $75.00M | — | — |
- Indivior Pharmaceuticals, Inc. showed an increase of +589.5% in Operating Income compared to the prior fiscal year.
- Over the 2022–2025 period, Indivior Pharmaceuticals, Inc.’s operating income has grown by 423.5% (from -$81.00 million to $262.00 million).
- The most recent figure is from Indivior Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: